SDC1 and Miyoshi myopathy: Following this line of reasoning, EZH2 inhibition utilizing UNC1999 was shown to overcome drug resistance and enhance the anti-MM activity of bortezomib and carfilzomib in resistant cell lines and CD138+ plasma cells isolated from MM patients [113].